-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
License in is a product introduction method, which is different from self-developed products or direct acquisition of companies.
Under the license in mode, the product importer can only introduce a certain product from the product authorizing party according to its own standards
.
Since the beginning of this year, License in transactions have continued to be popular in the pharmaceutical industry.
A large number of pharmaceutical companies are adopting the License-in model to enrich their product pipelines and accelerate innovation
.
For example, Shandong Luoxin, a subsidiary of Luoxin Pharmaceuticals, signed a "License Agreement" with Austrian Marinomed Biotech AG (hereinafter referred to as "Marinomed") and reached an agreement on the introduction of Budesolv® (Budesonide solution nasal spray) products.
In the future, Shandong Luoxin will obtain the exclusive right to develop, produce and commercialize this product in Greater China (including Mainland China, Hong Kong and Macau Special Administrative Regions, and Taiwan)
.
It is understood that Budesolv® is a new glucocorticoid budesonide agent, a hormone nasal spray.
It is the first water-soluble nasal spray developed based on Marinomed’s proprietary technology platform Marinosolv®.
At present, Budesolv® has been successfully completed in Europe.
Critical Phase III clinical trials necessary for marketing applications
.
In addition, Hansen Pharmaceuticals is currently vigorously entering the small nucleic acid market through license-in
.
In October of this year, Hansen Pharmaceuticals successively reached an agreement with OliX Pharmaceuticals and Silence Therapeuticsplc to use the two platforms to cooperate in the development of siRNA therapies.
The total amount of the two transactions was as high as 1.
75 billion US dollars
.
The industry expects that Hansen Pharmaceuticals, based on their positions in the development of siRNA treatments and their decades of scientific and technical experience, their technical platform and R&D capabilities are expected to bring important opportunities for Hansen Pharmaceuticals in the siRNA field
.
On the whole, a large number of local pharmaceutical innovation companies in China have become the main force of license-in, and up to now, the scope of influence of the license-in model is still expanding
.
It is worth mentioning that in addition to industry elites, more and more investment institutions have also begun to actively "save the game", using capital, contacts, project resources and many other advantages to create a star combination of luxury teams + projects, and take advantage of the trend to promote valuation along the way.
Rise, and take advantage of the capital market such as Hong Kong stocks and the Science and Technology Innovation Board to quickly IPO
.
In this regard, the industry believes that although the License in model has been controversial in the past
.
However, the BD capabilities and execution power of many companies that have developed to the present are constantly showing the market that the implementation of the license in strategy by pharmaceutical companies has great value, and this model is gradually becoming a new path for Chinese companies to improve their level of innovation
.
According to current industry trends, as domestic pharmaceutical companies continue to accelerate innovation, it is expected that license in may continue to increase in the future
.
However, it is worth noting that as more and more people enter the game, the price of license in may rise, and there may even be a certain degree of valuation bubble
.
In addition, regulators and the market may also be more cautious about the license in model
.
It is reported that in September this year, Haihe Pharmaceuticals IPO was officially rejected
.
Within a week, GK Gene's IPO was also rejected
.
Judging from the Shanghai Stock Exchange’s announcement, the supervisory authority has doubts about the “scientific innovation content” of Jikai Gene and Haihe Medicine, and believes that the issuer has not fully disclosed its independent research and development capabilities and technological advancement
.
In this context, the industry believes that the capital market will still be more inclined to pharmaceutical companies with independent innovation capabilities.
Therefore, although the license in model will help accelerate the expansion of the product pipeline of pharmaceutical companies, it cannot rely on this model for a long time.
Companies still need to continuously improve their R&D and innovation capabilities on their own
.
Under the license in mode, the product importer can only introduce a certain product from the product authorizing party according to its own standards
.
Since the beginning of this year, License in transactions have continued to be popular in the pharmaceutical industry.
A large number of pharmaceutical companies are adopting the License-in model to enrich their product pipelines and accelerate innovation
.
For example, Shandong Luoxin, a subsidiary of Luoxin Pharmaceuticals, signed a "License Agreement" with Austrian Marinomed Biotech AG (hereinafter referred to as "Marinomed") and reached an agreement on the introduction of Budesolv® (Budesonide solution nasal spray) products.
In the future, Shandong Luoxin will obtain the exclusive right to develop, produce and commercialize this product in Greater China (including Mainland China, Hong Kong and Macau Special Administrative Regions, and Taiwan)
.
It is understood that Budesolv® is a new glucocorticoid budesonide agent, a hormone nasal spray.
It is the first water-soluble nasal spray developed based on Marinomed’s proprietary technology platform Marinosolv®.
At present, Budesolv® has been successfully completed in Europe.
Critical Phase III clinical trials necessary for marketing applications
.
In addition, Hansen Pharmaceuticals is currently vigorously entering the small nucleic acid market through license-in
.
In October of this year, Hansen Pharmaceuticals successively reached an agreement with OliX Pharmaceuticals and Silence Therapeuticsplc to use the two platforms to cooperate in the development of siRNA therapies.
The total amount of the two transactions was as high as 1.
75 billion US dollars
.
The industry expects that Hansen Pharmaceuticals, based on their positions in the development of siRNA treatments and their decades of scientific and technical experience, their technical platform and R&D capabilities are expected to bring important opportunities for Hansen Pharmaceuticals in the siRNA field
.
On the whole, a large number of local pharmaceutical innovation companies in China have become the main force of license-in, and up to now, the scope of influence of the license-in model is still expanding
.
It is worth mentioning that in addition to industry elites, more and more investment institutions have also begun to actively "save the game", using capital, contacts, project resources and many other advantages to create a star combination of luxury teams + projects, and take advantage of the trend to promote valuation along the way.
Rise, and take advantage of the capital market such as Hong Kong stocks and the Science and Technology Innovation Board to quickly IPO
.
In this regard, the industry believes that although the License in model has been controversial in the past
.
However, the BD capabilities and execution power of many companies that have developed to the present are constantly showing the market that the implementation of the license in strategy by pharmaceutical companies has great value, and this model is gradually becoming a new path for Chinese companies to improve their level of innovation
.
According to current industry trends, as domestic pharmaceutical companies continue to accelerate innovation, it is expected that license in may continue to increase in the future
.
However, it is worth noting that as more and more people enter the game, the price of license in may rise, and there may even be a certain degree of valuation bubble
.
In addition, regulators and the market may also be more cautious about the license in model
.
It is reported that in September this year, Haihe Pharmaceuticals IPO was officially rejected
.
Within a week, GK Gene's IPO was also rejected
.
Judging from the Shanghai Stock Exchange’s announcement, the supervisory authority has doubts about the “scientific innovation content” of Jikai Gene and Haihe Medicine, and believes that the issuer has not fully disclosed its independent research and development capabilities and technological advancement
.
In this context, the industry believes that the capital market will still be more inclined to pharmaceutical companies with independent innovation capabilities.
Therefore, although the license in model will help accelerate the expansion of the product pipeline of pharmaceutical companies, it cannot rely on this model for a long time.
Companies still need to continuously improve their R&D and innovation capabilities on their own
.
